Keensight Capital-backed Symeres to acquire Organix.

Keensight Capital-backed Symeres, a European drug discovery contract research organization, agreed to acquire Organix, a provider of synthesis services across all areas of organic chemistry. Financial terms were not disclosed. "We are proud to become part of the Symeres family where we have found a trusted partner that shares our values and business philosophy of strong customer focus. The added expertise that the deal brings will allow Organix to better serve our clients by providing additional access to state-of-the-art cGMP services. We look forward to being a part of this innovative and science-driven organization," Anu Mahadevan, Organix CEO.